| Angioedemas, Hereditary
Cinryze vs Kalbitor
Side-by-side clinical, coverage, and cost comparison for angioedemas, hereditary.Deep comparison between: Cinryze vs Kalbitor with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsKalbitor has a higher rate of injection site reactions vs Cinryze based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Kalbitor but not Cinryze, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Cinryze
Kalbitor
At A Glance
IV infusion
Every 3-4 days
C1 esterase inhibitor (serpin)
SC injection
As needed
Plasma kallikrein inhibitor
Indications
- Angioedemas, Hereditary
- Angioedemas, Hereditary
Dosing
Angioedemas, Hereditary (adults and adolescents 12 years and above) 1,000 IU IV every 3 or 4 days at 1 mL/min (10 min); for inadequate responders, doses up to 2,000 IU (not exceeding 80 IU/kg) every 3 or 4 days may be considered.
Angioedemas, Hereditary (pediatric patients 6-11 years) 500 IU IV every 3 or 4 days at 1 mL/min (5 min); dose may be adjusted up to 1,000 IU every 3 or 4 days based on individual response.
Angioedemas, Hereditary 30 mg (3 mL) subcutaneously in three 10 mg (1 mL) injections per attack; an additional 30 mg may be administered within 24 hours if the attack persists.
Contraindications
- Life-threatening immediate hypersensitivity reactions, including anaphylaxis, to CINRYZE or any of its excipients
- Known clinical hypersensitivity to KALBITOR
Adverse Reactions
Most common (>=5%) Headache, nausea, rash, vomiting, fever
Serious Cerebrovascular accident
Postmarketing Local infusion site reactions (inflammation or hematoma at infusion site), hypersensitivity
Most common (>=3%) Headache, nausea, diarrhea, pyrexia, injection site reactions, nasopharyngitis
Serious Hypersensitivity reactions including anaphylaxis
Postmarketing Similar adverse reactions as observed in clinical trials
Pharmacology
C1 esterase inhibitor (serpin) that regulates complement and intrinsic coagulation (contact system) pathway activation; suppresses contact system activation by inactivating plasma kallikrein and factor XIIa, modulating vascular permeability by preventing bradykinin generation.
Plasma kallikrein inhibitor; ecallantide is a potent, selective, reversible inhibitor of plasma kallikrein that blocks its binding site, reducing the conversion of HMW kininogen to bradykinin and thereby treating symptoms during acute episodic attacks of HAE.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Cinryze
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (5/12) · Qty limit (9/12)
Kalbitor
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Cinryze
- Covered on 4 commercial plans
- PA (2/8) · Step Therapy (0/8) · Qty limit (0/8)
Kalbitor
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Cinryze
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Kalbitor
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Hereditary Angioedema - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Hereditary Angioedema - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
CinryzeView full Cinryze profile
KalbitorView full Kalbitor profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.